National registry for Takayasu arteritis in China
China Takayasu Arteritis Registry (CTA Registry)
This study is creating a national registry for Takayasu arteritis in China to collect information that can help improve treatment and understanding of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 5 Years to 80 Years |
| Sex | All |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT02964364 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a national registry for Takayasu arteritis (TA) in China to gather real-world data on the disease's characteristics, diagnosis, activity, severity, treatment, and outcomes. By analyzing this information, researchers hope to enhance understanding of the epidemiology and pathophysiology of TA, particularly in the Chinese Han population. The study will also explore the relationship between specific cytokines and HLA gene alleles with TA activity. The ultimate goal is to develop effective monitoring and treatment strategies for patients with TA.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Takayasu arteritis who are under 40 years of age and exhibit specific clinical symptoms.
Not a fit: Patients with vessel lesions solely due to atherosclerosis or those with giant cell arteritis may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved monitoring and treatment strategies for patients with Takayasu arteritis.
How similar studies have performed: While there have been studies on Takayasu arteritis, this registry approach is relatively novel and aims to fill significant gaps in understanding the disease in the Chinese population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at disease onset \< 40 years. (Development of symptoms or findings related to Takayasu arteritis at age \<40 years) * Claudication of extremities. (Development and worsening of fatigue and discomfort in muscles of 1 or more extremity while in use, especially the upper extremities) * Decreased brachial artery pulse. (Decreased pulsation of 1 or both brachial arteries) * BP difference \>10 mm Hg. (Difference of \>10 mm Hg in systolic blood pressure between arms) * Bruit audible on auscultation over 1 or both subclavian arteries or abdominal aorta. * Arteriogram abnormality. (Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes usually focal or segmental) Exclusion Criteria: * Vessel lesions that could be entirely due to atherosclerosis. * Giant cell arteritis or other infectious forms of large vessel vasculitis.
Where this trial is running
Beijing, Beijing Municipality
- Fuwai Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Aimin Dang, MD,PhD
- Email: aimindangfw@gmail.com
- Phone: +8610-88322131
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.